import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "vasoactive-intestinal-peptide-vip-research-guide",
  title: "Vasoactive Intestinal Peptide (VIP): Mechanisms, Research Findings, and Study Applications",
  description:
    "A research-focused overview of Vasoactive Intestinal Peptide (VIP) — a 28-amino acid neuropeptide with documented roles in immune modulation, bronchodilation, circadian regulation, and neuroprotection. Covers receptor biology, preclinical evidence, and research design considerations.",
  category: "Compound Profiles",
  readMinutes: 10,
  publishedAt: "2026-06-10",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide first isolated from porcine small intestine in 1970 by Said and Mutt. Despite its name — derived from its original identification as a vasodilatory agent — VIP has since been characterized as one of the most pleiotropic signaling molecules in the mammalian nervous and immune systems. Its receptor distribution spans the CNS, peripheral nervous system, gastrointestinal tract, lungs, immune cells, and cardiovascular tissue, making it a compound of broad scientific interest.",
    },
    {
      type: "paragraph",
      text: "This article provides a research-oriented overview of VIP's biology, the receptor systems it engages, what the preclinical literature documents, and the methodological considerations relevant to designing studies with this peptide.",
    },
    {
      type: "heading",
      text: "Structure and Receptor Biology",
    },
    {
      type: "paragraph",
      text: "VIP belongs to the glucagon/secretin superfamily of peptides — a structural family that includes PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide), secretin, glucagon, and GIP. Its sequence is: His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (28 AA). The peptide is encoded by the VIP gene on chromosome 6 in humans and undergoes post-translational processing from a larger precursor.",
    },
    {
      type: "paragraph",
      text: "VIP signals through two primary G-protein coupled receptors: VPAC1 (VIPR1) and VPAC2 (VIPR2). Both couple primarily to Gs proteins, stimulating adenylyl cyclase and elevating intracellular cAMP. VPAC1 is widely expressed across peripheral tissues and the CNS; VPAC2 shows more restricted expression with notable concentration in the suprachiasmatic nucleus (SCN), pancreas, and smooth muscle. A third receptor — PAC1 — is shared with PACAP and shows lower VIP affinity.",
    },
    {
      type: "subheading",
      text: "Downstream Signaling",
    },
    {
      type: "paragraph",
      text: "cAMP elevation via VPAC receptors activates protein kinase A (PKA), which phosphorylates downstream targets including CREB (cAMP response element-binding protein), ion channels, and cytoskeletal proteins. In immune cells, PKA activation drives anti-inflammatory gene programs. In smooth muscle, it drives relaxation. In neurons, it modulates excitability and neurotransmitter release. VIP also activates phospholipase C via Gq-coupled pathways in certain cell types, adding IP3/DAG-mediated calcium signaling to its downstream repertoire.",
    },
    {
      type: "heading",
      text: "Immune Modulation Research",
    },
    {
      type: "paragraph",
      text: "VIP's role as an immunomodulatory peptide is among the most extensively documented aspects of its biology. Preclinical research has consistently demonstrated anti-inflammatory effects across multiple disease models.",
    },
    {
      type: "subheading",
      text: "T-Cell and Cytokine Effects",
    },
    {
      type: "paragraph",
      text: "VIP suppresses Th1 cytokine production (TNF-α, IFN-γ, IL-6, IL-12) while promoting Th2 responses and regulatory T-cell (Treg) differentiation. In murine models of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, VIP administration has been shown to reduce local and systemic inflammatory markers. The peptide also induces IL-10 production — a key anti-inflammatory cytokine — from macrophages and dendritic cells.",
    },
    {
      type: "subheading",
      text: "Dendritic Cell Tolerogenicity",
    },
    {
      type: "paragraph",
      text: "A particularly well-characterized VIP effect involves its action on dendritic cells (DCs). VIP drives DCs toward a tolerogenic phenotype — reducing MHC-II expression, lowering costimulatory molecule expression (CD80, CD86), and reducing IL-12 secretion. This tolerogenic DC profile promotes Treg induction over effector T-cell priming, with implications for autoimmune disease research models.",
    },
    {
      type: "heading",
      text: "Pulmonary and Cardiovascular Research",
    },
    {
      type: "paragraph",
      text: "VIP is a potent bronchodilator and pulmonary vasodilator. It relaxes airway smooth muscle via cAMP-mediated mechanisms and inhibits bronchoconstriction in rodent models of asthma. In pulmonary arterial hypertension (PAH) research, VIP has been studied for its ability to reduce pulmonary vascular resistance. Some clinical observations suggested VIP deficiency in PAH patients, spurring interest in exogenous VIP administration as a research intervention.",
    },
    {
      type: "paragraph",
      text: "Systemically, VIP causes peripheral vasodilation, reduces arterial blood pressure in animal models, and has been studied for cardioprotective effects including reduction of ischemia-reperfusion injury markers. Its vasodilatory action derives from both direct smooth muscle relaxation and NO-dependent mechanisms in endothelial cells.",
    },
    {
      type: "heading",
      text: "Circadian Biology and SCN Research",
    },
    {
      type: "paragraph",
      text: "VIP and its VPAC2 receptor are critical components of the suprachiasmatic nucleus (SCN) — the master circadian clock in mammals. VIP is released by SCN neurons in a circadian pattern and coordinates intercellular synchronization within the nucleus. Research using VPAC2-knockout mice has demonstrated profound circadian desynchrony, establishing the VIP/VPAC2 axis as essential for clock function.",
    },
    {
      type: "paragraph",
      text: "This makes VIP a research tool of interest for studying circadian disruption, jet lag models, shift-work biology, and the metabolic consequences of clock dysfunction. Researchers investigating circadian peptide signaling often use VIP agonists and antagonists to probe the SCN's synchronization mechanisms.",
    },
    {
      type: "heading",
      text: "Neuroprotective and Neurotrophic Research",
    },
    {
      type: "paragraph",
      text: "In neurological models, VIP has demonstrated neuroprotective properties in multiple paradigms. It reduces glutamate-induced excitotoxicity, attenuates oxidative stress markers, and promotes neuronal survival in models of hypoxic injury and Alzheimer's-like pathology. VIP stimulates ADNF (Activity-Dependent Neurotrophic Factor) secretion from astrocytes — a mechanism proposed to mediate some of its neuroprotective effects.",
    },
    {
      type: "paragraph",
      text: "In Parkinson's-related research, VIP has been studied for its capacity to reduce dopaminergic neuron loss in MPTP-treated animal models. The anti-neuroinflammatory properties of VIP — mediated through microglial inhibition and reduction of CNS TNF-α and IL-1β — likely contribute to this neuroprotection.",
    },
    {
      type: "heading",
      text: "GI and Metabolic Research",
    },
    {
      type: "paragraph",
      text: "VIP was originally identified as a GI regulatory peptide and retains a well-characterized role in gut physiology. It stimulates intestinal secretion, relaxes GI smooth muscle (acting as an inhibitory neurotransmitter in the enteric nervous system), and promotes pancreatic bicarbonate and enzyme secretion. Vasoactive intestinal peptide-secreting tumors (VIPomas) — which cause the clinical syndrome of profuse watery diarrhea — illustrate the peptide's physiological potency at supraphysiological levels.",
    },
    {
      type: "paragraph",
      text: "In metabolic research, VIP has been studied for effects on insulin secretion, adipocyte function, and energy homeostasis. Its pancreatic effects include stimulation of insulin release and inhibition of glucagon secretion, suggesting relevance to glucose metabolism research.",
    },
    {
      type: "heading",
      text: "Research Design Considerations",
    },
    {
      type: "paragraph",
      text: "VIP has a short plasma half-life — approximately 1–2 minutes in vivo due to rapid degradation by neutral endopeptidases and dipeptidyl peptidase IV (DPP-IV). This pharmacokinetic profile makes systemic IV administration challenging for sustained effects. In vitro studies and ex vivo tissue preparations circumvent this limitation. For in vivo work, researchers typically use: (1) local intranasal delivery for CNS effects, (2) intrathecal or intracerebral administration, (3) continuous infusion, or (4) VIP analogs with enhanced metabolic stability.",
    },
    {
      type: "paragraph",
      text: "Several VIP analogs have been developed for research use to extend half-life while maintaining receptor selectivity. Peptide modifications including N-terminal acetylation, C-terminal amidation, and incorporation of non-natural amino acids have produced compounds with substantially extended activity windows — enabling cleaner in vivo experimental designs.",
    },
    {
      type: "subheading",
      text: "Receptor Selectivity Tools",
    },
    {
      type: "paragraph",
      text: "VPAC1-selective agonists ([K15,R16,L27]VIP(1-7)/GRF(8-27)-NH2 and analogs) and VPAC2-selective agonists (Ro 25-1553, Bay 55-9837) are available for receptor subtype dissection. VPAC1/2 antagonists based on the PACAP antagonist backbone (e.g., PG 97-269, VIP(6-28)) allow receptor contribution to be established in pharmacological studies.",
    },
    {
      type: "heading",
      text: "Sourcing and Quality Requirements",
    },
    {
      type: "paragraph",
      text: "As a 28-amino acid peptide, VIP synthesis quality is critical. Common sources of variation include: incomplete synthesis (truncated sequences), racemization at sensitive residues, oxidation of methionine at position 17, and aggregation in solution. Researchers should require HPLC purity ≥98%, mass spectrometry confirmation of the correct molecular weight (3326.8 Da for the free acid form), and documentation of endotoxin levels for in vivo use.",
    },
    {
      type: "divider",
    },
    {
      type: "disclaimer",
      text: "For research purposes only. Not intended for human use or administration.",
    },
  ],
};
